Latest in Tag: Rameda Highlight
Latest in Tag: Rameda
Rameda’s profits jump by 101.1% in 1H 2022
Expansion in NPM was driven by growing operating profitability coupled with decreasing interest expenses throughout the period.
Rameda acquires pharmaceutical drug expected to contribute EGP 30m to revenues
The company said that it will benefit from the growth factors that characterise the pharmaceutical product, as it recorded a compound annual growth in sales at the market level by 87% between 2018 and 2021.
IFC partners with Rameda to ‘green’ its operations in Egypt
In a Tuesday press statement the IFC said that through this partnership, it will help Rameda adopt solutions that reduce its carbon and water footprints and improve efficiencies in materials and resource usage.
Rameda begins production of coronavirus antiviral drug ‘Molnupiravir Rameda’
The drug was developed by the American company Merck and is an oral antiviral drug approved for the treatment of adults infected with COVID-19.
Rameda’s new antiviral medication successfully opens up new export markets
Levant region has lion’s share of group’s export volumes in Q1 2021
Rameda for pharmaceuticals expects COVID-19 to continue until H1 of 2022
Company plans to launch 8-10 products in 2021, eyes entry in new markets including Saudi Arabia, Kuwait, Bahrain, UAE, Pakistan
Rameda posts neutral results with revenues of EGP 205m
Revenues reflect downturn of 11.8% q-o-q, but rise of 5.6% y-o-y
Rameda gets EDA approval to price two coronavirus medicines
Rameda started last month manufacturing Anviziram, which contains the active pharmaceutical ingredient Favipiravir which has been adopted as part of the COVID-19 treatment protocol in Russia, China, and India. It will be released at EGP 1,260 per 40-tablet package.
Rameda receives export requests for its COVID-19 drug Anviziram
The pharmaceuticals firm awaits the Egyptian Ministry of Health’s approval to export the antiviral drug, Morsy noted.
Rameda starts manufacturing of generic Anviziram for COVID-19 treatment
EDA also grants approval for Rameda to begin manufacturing intravenous Remedisivir vials
Rameda reports 22% top line, 196% net income growth in Q1 2020
Company faced COVID-19 crisis through targeted policies ensuring it continuously provides patients with medication.
Rameda offers free home delivery of prescription drugs amid Covid-19 outbreak
Initiative to last for three months over three phases
Rameda acquires one of best-selling generic NSAIDs in Egypt
According to IQVIA, a world leader in advanced data analytics covering pharmaceutical sales data in the Egyptian private market, the molecule has recorded revenues of EGP 71.3 million in 2019. These figures are based on the product’s retail price.
Rameda Reports double-digit topline growth in FY19
Plans to launch at least 12 new molecules each year in the medium-term
Rameda plans to introduce new drugs for the digestive system, diabetes, nerves, and antibiotics
New acquisitions opportunities to produce pharmaceutical products that the company does not cover: Morsi
Rameda targets stock market debut in 4Q 2019
Company to use IPO to fund opportunistic acquisition of pharmaceutical companies